News - Santarus


Current filters:


Popular Filters

US FDA accepts Ruconest filing from Santarus and Pharming


US drugmaker Santarus (Nasdaq: SNTS) and Netherlands-based Pharming Group (NYSE Euronext: PHARM) say…

BiotechnologyCardio-vascularNorth AmericaPharmingRare diseasesRegulationRuconestSantarus

Pharming and Santarus file BLA for Ruconest with US FDA


Netherlands-based Pharming Group (NYSE Euronext: PHARM) and US licensee Santarus (Nasdaq: SNTS) have…

North AmericaPharmaceuticalPharmingRare diseasesRegulationRuconestSantarus

Pharming gets $10 million milestone from Santarus on Ruconest progress


Loss-making Dutch biotech company Pharming Group NV (NYSE Euronext: PHARM) said yesterday that, following…

BiotechnologyFinancialPharmingRare diseasesResearchRuconestSantarus

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld


US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Santarus and Depomed expand US deal on Glumetza


US drugmakers Santarus (Nasdaq: SNTS) and Depomed (Nasdaq: DEPO) have entered into a new commercialization…

DepomedDiabetesGlumetzaLicensingNorth AmericaPharmaceuticalSantarus

Back to top